VivoSeq
Oncology

Malignant Mesothelioma

61

Pipeline Programs

8

Active Trials

26

Companies Involved

Malignant Mesothelioma is a moderately active landscape with 61 programs across 26 companies. The most active players are Kenvue Brands, Sun Pharma, Parkedale. 1 program is in Phase 3.

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

6/100

Mech. Concentration

8/100

Completion Rate

76/100

Attrition Rate

15/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

83%

Small molecule

52 of 63 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody711%Protein / enzyme23%Antibody–drug conjugate12%Vaccine12%

Small molecule leads; the ring shows all 63 classified programs, each share of the total. Modality classified for 100% of 66 pipeline programs.

Trial Status

61

clinical trials

Completed32 · 52%
Unknown status9 · 15%
Terminated8 · 13%
Active, not recruiting4 · 7%
Recruiting3 · 5%
Approved for marketing1 · 2%
Other4 · 7%

Trial Activity

61 trials

Pembrolizumab in Treating Patients With Malignant Mesothelioma
Active, not recruiting·UUniversity of Chicago·Phase 2·NCT02399371·65 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)